Anzeige
Mehr »
Login
Mittwoch, 29.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Künstliche Intelligenz lässt die Nachfrage explodieren - so profitieren Anleger
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JX3U | ISIN: US8684591089 | Ticker-Symbol: S49
Frankfurt
29.05.24
08:00 Uhr
24,800 Euro
-0,200
-0,80 %
1-Jahres-Chart
SUPERNUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SUPERNUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
24,60025,00014:46
24,80025,00014:25

Aktuelle News zur SUPERNUS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoSUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
DoSupernus Pharmaceuticals, Inc.: Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy59SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May...
► Artikel lesen
09.05.Supernus Pharmaceuticals, Inc.: Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures1
09.05.Supernus Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary2
08.05.SUPERNUS PHARMACEUTICALS, INC. - 10-Q, Quarterly Report1
08.05.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
01.05.Supernus Pharmaceuticals, Inc.: Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story1
24.04.Supernus Pharmaceuticals, Inc.: Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 20242
24.04.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
08.04.FDA swats away Supernus' Parkinson's disease infusion pump for 3rd time2
08.04.Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease1
08.04.US FDA declines to approve Supernus' drug-device combination for Parkinson's disease1
08.04.Supernus stock slides as FDA rejects Parkinson's disease infusion device1
08.04.Supernus Pharmaceuticals, Inc.: Supernus Provides Regulatory Update for SPN-830128ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
► Artikel lesen
08.04.SUPERNUS PHARMACEUTICALS, INC. - 8-K, Current Report1
25.03.Supernus Pharmaceuticals exec sells over $500k in stock1
22.03.Supernus Pharmaceuticals exec sells $14.1k in stock1
15.03.Supernus Pharmaceuticals executive sells over $2.1m in stock3
06.03.Supernus Pharmaceuticals, Inc.: Supernus to Participate in Two Upcoming Investor Conferences1
06.03.Earnings call: Supernus Pharmaceuticals reports growth despite challenges3
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1